Table 1.
Baseline Clinicopathological Features in the Present Extensive SCLC Cohort (n=224)
| Groups | N | AAPR | P Value | |
|---|---|---|---|---|
| <0.35 (n=53) | ≥0.35 (n=171) | |||
| Age | 224 | 60.57 ± 8.76 | 60.49 ± 8.75 | 0.651 |
| Age Group | 0.599 | |||
| <60 | 100 | 22 (41.51%) | 78 (45.61%) | |
| ≥60 | 124 | 31 (58.49%) | 93 (54.39%) | |
| Sex | 0.034 | |||
| Male | 197 | 51 (96.23%) | 146 (85.38%) | |
| Female | 27 | 2 (3.77%) | 25 (14.62%) | |
| Smoking History | 0.592 | |||
| Never | 40 | 8 (15.09%) | 32 (18.71%) | |
| Ever | 179 | 43 (81.13%) | 136 (79.53%) | |
| Unknow | 5 | 2 (3.77%) | 3 (1.75%) | |
| ECOG | 0.259 | |||
| 0–1 | 170 | 40 (75.47%) | 130 (76.02%) | |
| ≥2 | 31 | 10 (18.87%) | 21 (12.28%) | |
| Unknown | 23 | 3 (5.66%) | 20 (11.70%) | |
| Bone Metastasis | 0.052 | |||
| No | 159 | 32 (60.38%) | 127 (74.27%) | |
| Yes | 65 | 21 (39.62%) | 44 (25.73%) | |
| Lung Metastasis | 0.310 | |||
| No | 161 | 41 (77.36%) | 120 (70.18%) | |
| Yes | 63 | 12 (22.64%) | 51 (29.82%) | |
| Brain Metastasis | 0.244 | |||
| No | 187 | 47 (88.68%) | 140 (81.87%) | |
| Yes | 37 | 6 (11.32%) | 31 (18.13%) | |
| Liver Metastasis | 0.069 | |||
| No | 169 | 35 (66.04%) | 134 (78.36%) | |
| Yes | 55 | 18 (33.96%) | 37 (21.64%) | |
| Adrenal Gland Metastasis | 0.112 | |||
| No | 187 | 48 (90.57%) | 139 (81.29%) | |
| Yes | 37 | 5 (9.43%) | 32 (18.71%) | |
| Malignant Pleural Effusion | 0.626 | |||
| No | 154 | 35 (66.04%) | 119 (69.59%) | |
| Yes | 70 | 18 (33.96%) | 52 (30.41%) | |
| Sum of Metastatic Organs | 0.081 | |||
| <2 | 137 | 27 (50.94%) | 110 (64.33%) | |
| ≥2 | 87 | 26 (49.06%) | 61 (35.67%) | |
| Efficacy of First-line Treatment | 0.076 | |||
| PR | 106 | 28 (52.83%) | 78 (45.61%) | |
| SD | 37 | 11 (20.75%) | 26 (15.20%) | |
| PD | 13 | 5 (9.43%) | 8 (4.68%) | |
| Unknown | 68 | 9 (16.98%) | 59 (34.50%) | |
| Sum of Treatment Lines | 0.342 | |||
| First-line | 163 | 42 (79.25%) | 121 (70.76%) | |
| Second-line | 43 | 9 (16.98%) | 34 (19.88%) | |
| Third-line or more | 18 | 2 (3.77%) | 16 (9.36%) | |
Abbreviations: AAPR, albumin-to-alkaline phosphatase ratio; SCLC, small-cell lung cancer; ECOG PS, Performance Status of East Cooperative Oncology Group; PR, partial response; SD, stable disease; PD, disease progression.